Cellbion
308430
Company Profile
Business description
Cellbion is a radiopharmaceutical innovation engaged in the development and commercialization of radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology. Its pipeline products targeted indications are Prostate Cancer radiotherapy, Solid Tumors Diagnosis, Multiple Cancer types, and Others.
Contact
103, Daehak-ro
6th Floor
Jongno-gu
Seoul03080
KORT: +82 27433311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
58
Stocks News & Analysis
stocks
Undervalued by 17%, this US cybersecurity leader is a buy for 2026
Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks
Tough conditions for ASX listed wagering leader
Wagering continues to be challenged in Australia.
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,045.90 | 27.80 | -0.31% |
| CAC 40 | 8,284.76 | 50.84 | 0.62% |
| DAX 40 | 25,140.08 | 12.62 | 0.05% |
| Dow JONES (US) | 49,266.11 | 270.03 | 0.55% |
| FTSE 100 | 10,078.61 | 33.92 | 0.34% |
| HKSE | 26,231.79 | 82.48 | 0.32% |
| NASDAQ | 23,480.02 | 104.26 | -0.44% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,696.25 | 20.61 | -0.15% |
| S&P 500 | 6,921.46 | 0.53 | 0.01% |
| S&P/ASX 200 | 8,717.80 | 29.10 | -0.33% |
| SSE Composite Index | 4,120.43 | 37.45 | 0.92% |